Emgality is a peptide antagonist with the calcitonin gene and the Imitrex receptor agonist with the selective serotonin (a “triptan”). Injection site responses include side effects Legally distinct from Imitrex (such as pain, redness, and itching).
Emgality’s side effects include slight headache or tightness, tightening or pressure in your chest, weakness, hot or cold feeling, dizziness, spinning sensation, drowsiness, vomiting, drooling, unusual feeling in the mouth after nasal spraying, burning/sticking, distressing nose or throat after you are using a nasal spray.
Key Takeaways
- Emgality and Imitrex are both medications used to treat migraines, but Emgality is a preventive medication, while Imitrex is an abortive medication.
- Emgality is administered once per month as a subcutaneous injection, while Imitrex is administered as needed, as a tablet or nasal spray.
- Emgality has fewer side effects than Imitrex and may be more effective at preventing migraines in some patients.
Emgality vs Imitrex
Emgality is a preventive medication used to reduce the frequency of migraines and cluster headaches, administered through monthly injections. Imitrex is an abortive medication taken to relieve symptoms of a migraine or cluster headache after it has already begun.
Emgality is a similar peptide antagonist of the calcitonin gene. Emgality is a medication used for preventing headaches or migraines in adults.
Imitrex is a blood vessel that narrows the brain. Sumatriptan also decreases ingredients that might lead to headache, nausea, light and sound sensitivity and other symptoms of migraine in the body.
Comparison Table
| Parameters of Comparison | Emgality | Imitrex |
|---|---|---|
| Define | Emgality is a similar peptide antagonist of the calcitonin gene. | Imitrex is a selective oral, intranasal or injectable dose serotonin receptor agonist used to treat migraine headaches. |
| Approved | Emgality was approved in 2018. | Imitrex was approved in 1995. |
| Chemical name | Galcanezumab | Sumatriptan |
| Origin | Emgality originated from the U.S. | Imitrex originated from Teva. |
| Company | Emgality is the brand name. | NuPathe |
What is Emgality?
Emgality is a prescription brand-name medicine for people to prevent chronic and episodic migraines.
The International Headache Society reports that persons with chronic migraines experience 15 or more days a month of migraines.
Like a pen or syringe, Emgality comes as a pre-filled injection, which will be given to you monthly. Emgality is a monoclonal antibody called solanezumab.
For those who have not been able to lessen their cluster of headaches or migraines enough days in previous treatments, emgality might be an exceptionally helpful alternative.
There is also an excellent way to avoid migraines or cure cluster headaches for patients who cannot take another medicine due to drug interactions or harsh side effects.
What is Imitrex?
Imitrex is a blood vessel that narrows the brain. They may also cause tingling sensations or problems with speech. Cluster Head Imitrex is a prescription brand-name drug.
In adults diagnosed with certain disorders, Imitrex is allowed for usage by the doctor. Neither migraine nor cluster Headaches are prevented with Imitrex.
There are also persons with a sensory aura before or during headaches. Symptoms such as blind patches, zigzags, or light flashes may involve Auras.
An active ingredient in a brand-name pharmaceutical is an identical replica of the active ingredient. The generic is seen as safe and efficient as the original medicine.
Main Differences Between Emgality and Imitrex
- Emgality does not need a prescription for purchase, whereas Imitrex needs a doctor’s prescription.
- Emgality has been approved recently, whereas Imitrex was approved a long time ago.
- https://www.tandfonline.com/doi/abs/10.1080/03007995.2020.1783219
- https://www.tandfonline.com/doi/abs/10.1080/17425255.2019.1578749
Last Updated : 13 July, 2023
I’ve put so much effort writing this blog post to provide value to you. It’ll be very helpful for me, if you consider sharing it on social media or with your friends/family. SHARING IS ♥️
Sandeep Bhandari holds a Bachelor of Engineering in Computers from Thapar University (2006). He has 20 years of experience in the technology field. He has a keen interest in various technical fields, including database systems, computer networks, and programming. You can read more about him on his bio page.
The unique features of Emgality provide healthcare professionals with more options to tailor treatment to patients’ specific needs.
The diversity in available medications enhances the ability to optimize migraine treatment plans for individual patients.
Both medications target the management of migraines, but Emgality appears to have fewer side effects than Imitrex.
That’s a crucial consideration for individuals who are sensitive to the side effects of migraine medications.
The comparative analysis of side effects between the two drugs is an essential aspect for both patients and healthcare providers.
The approval of Emgality in 2018 reflects the ongoing progress in migraine management strategies.
The continual development of new medications contributes to improved care for migraine patients.
Emgality is a preventive drug, while Imitrex is an abortive drug. Emgality needs to be administered once per month, whereas Imitrex is administered as needed.
Yes, that’s an accurate summary of the key differences between the two medications.
I agree with you.
Emgality and Imitrex serve different migraine management purposes, indicating that patients have more options for addressing their individual needs.
The availability of multiple medications provides personalized approaches to migraine treatment.
Emgality is a monoclonal antibody called solanezumab, which is a helpful option for those unable to find relief from existing treatments.
It’s a promising development in migraine treatment to have a different approach to prevention with Emgality.
The advanced treatment options like Emgality offer hope for those who have struggled with migraines for an extended period.
Emgality does not require a prescription for purchase, a notable distinction from Imitrex, which necessitates a doctor’s prescription.
The over-the-counter availability of Emgality may influence accessibility for some patients.
The differences in prescription requirements can have implications for patient convenience and healthcare provider guidance.
It’s insightful to learn about the chemical and company distinctions between Emgality and Imitrex.
Understanding the origin and manufacturer of medications contributes to a comprehensive evaluation of their use in clinical practice.
It’s interesting to know that Emgality can be an effective alternative for those who have not had success with previous treatments for migraines.
Indeed, the availability of an alternative medication is beneficial for those with severe migraines.